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Cerebrovascular accidents (CVA) are serious complications of sickle cell anemia (SS) in
children. Factors that predispose children to this complication are not well established.
In an effort to elucidate the risk factors associated with CVA in SS, we have determined
the a-globin genotype and the bS haplotype of children with this complication. Among
700 children with SS followed at Children’s Hospital of Michigan, 41 (6%) are on chronic
transfusions because of stroke due to cerebral infarction. The mean age of patients with
CVA at the time of stroke was 5.6 ± 3.2 years (mean ± SD). The male/female ratio was 2/3.
Only 8 of 41 patients (19.5%) had one a-gene deletion, compared to the reported preva-
lence of 30% in African-Americans. None of the patients had two a-gene deletions, and
two (5%) had five a-genes. These findings are different than those in our adult patients
with SS, where the prevalence of − a/−a and aaa/aa is 4% and <2%, respectively. Ten
different bS-haplotypes were detected in the patients studied. The majority of the patients
(31%) were doubly heterozygous for the Ben/CAR haplotypes followed by Ben/Ben, Ben/
Sen, and CAR/CAR haplotypes, respectively. The prevalence of these haplotypes, with
the exception of the CAR/CAR haplotype, was higher in females than males. All the
patients with CAR/CAR haplotype were males, had four a-genes, and ranked third in
prevalence. Three patients were heterozygous for the Cameron haplotype. The Cameron
and atypical haplotypes were more prevalent than reported in patients with SS at large.
The data suggest that CVA in children seems to occur more frequently in females and in
patients with certain bS haplotype. a-Gene deletion seems to offer a protective effect
against this complication. Neonates with four or more a-genes whose bS haplotype is
Ben/CAR, atypical, or CAR/CAR seem to be at a higher risk for CAV than other patients.
A prospective study on a larger group of patients with or without CVA may clarify this
issue. Am. J. Hematol. 67:179–182, 2001. © 2001 Wiley-Liss, Inc.
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INTRODUCTION
Overt stroke is a serious, devastating complication of
the sickling disorders, with reported prevalence of 8.5%
to 17% [1–3]. There is a prohibitively high risk of recur-
rences in the un-transfused patient, leading to progres-
sively increasing disability [4]. Preventive therapy with
chronic transfusion has been shown to decrease recur-
rence rates from 67% in the un-transfused patient to
<10% [4,5]. This complication has been recently pro-
posed as an indication for more invasive curative at-
tempts with bone marrow transplantation [6]. Bone mar-
row transplantation for hemoglobinopathies has a more
favorable outcome when performed early in the course of
patients at risk for complications from their disease.
There is thus a need to identify markers that could dis-
tinguish patients at high risk for this complication at an
early age. The co-existence ofa-thalassemia with SS has
been shown to have an inhibitory effect on intracellular
polymer formation. Our hypothesis was thata- halasse-
mia, with its tendency to retard intracellular polymer for-
mation, is protective against the development of CNS
disease in SS, and, thus, the prevalence ofa-thalassemia
in a cohort of patients with stroke is lower than expected.
A secondary hypothesis was that there is an association
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between thebS haplotype and the prevalence of stroke.
The aim of this study was to evaluate the prevalence of
a-thalassemia and the distribution ofbS haplotype
among children with CVA from SS in a single large
institution.
METHODS
Forty-one consecutive patients with SS who presented
to Children’s Hospital of Michigan with clinical signs
and symptoms of CVA were subjects of this study. The
diagnosis of CNS infarction was confirmed by imaging
studies in all cases.a-Genotypes were determined by
digesting genomic DNA withBamHI and BglII restric-
tion endonucleases followed by Southern blot hybridiza-
tion with a-gene probe [7,8]. Genomic DNA was pre-
pared from peripheral leukocytes as described previously
[9] and digested with the indicated restriction endonucle-
ases according to the recommendations of the manufac-
turer.
bS-Globin haplotypes were determined by restriction
endonuclease digestion of genomic DNA followed by
Southern blot transfer and hybridization with radiola-
beled probes that detect the presence or absence of en-
zyme cleavage sites [10]. The pattern of nine polymor-
phic restriction sites within and around thebS-gene
cluster were determined. These sites were as follows:
HincII 58 to «, XmnI 58 to Gg, HindIII within Gg and Ag,
HincII within and 38 to cb, AvaII within b, andHpaI and
BamHI 38 to b [11].
Hematological data were obtained at steady-state rou-
tine visits. Patients had not received transfusions for at
least 4 months before these data were obtained. In all
instances, these data were obtained prior to development
of stroke symptoms. Fetal hemoglobin (Hb F) was quan-
titated using the alkali denaturation technique [12]; all
individuals were more than 2 years of age at the time of
Hb F measurement.
RESULTS
The mean age of the patients at the time of their first
CVA was 5.6 ± 3.2 years (mean ± SD). The male to
female ratio was about 2:3. Pre-transfusion Hb F levels
after the age of 2 years were available in seven patients.
Hb F level ranged from 2.9% to 20.3%, with a mean of
10.3%. Mean pre-transfusion steady-state hemoglobin
levels, MCV, and other red cell indices were not unusual
nor was the mean total WBC.
Table I shows the distribution ofa-genotypes in the
children with SS and CVA. Noteworthy is that none of
the children studied had the −a/−a genotype, 19% had
the -a/aa genotype, 76% had theaa/aa genotype, and
5% had theaaa/aa genotype. The prevalence of all
these categories was higher in females than males.
Ten differentbS-haplotypes were detected in the pa-
tients studied. The definition of these haplotypes using
nine endonuclease restriction sites was as previously de-
scribed [11]. The distribution of these haplotypes among
the patients studied is shown in Table II. The majority of
the patients (32%) were doubly heterozygous for the
Ben/CAR haplotypes followed by Ben/Ben, Ben/Sen,
and CAR/CAR haplotypes, respectively. Again, the
prevalence of these haplotypes, with the exception of the
CAR/CAR haplotype, was higher in females than males.
Table II lists the distribution of theb-haplotypes accord-
ing to the a-genotype of the patients studied. In this
format, the majority of the patients, again, had four
a-genes and Ben/CAR. Noteworthy is that all the pa-
tients with CAR/CAR haplotype had foura-genes and
ranked third in prevalence.
DISCUSSION
Our major goal in this study has been to identify
unique characteristics, if any, in children with SS and
CVA. Such characteristics may be markers of severe dis-
ease in neonates and could identify candidates for ag-
gressive approach to therapy that includes bone marrow
transplantation. A major finding in this study is that none
of the children with CVA had twoa-gene deletions (−a/
−a genotype). Moreover, 76% of the patients had four
a-genes (aa/aa genotype). Thea-gene distribution in
our pediatric patients with stroke is different than that
reported in African Americans with SS at large where the
prevalence ofaa/aa genotype is about 65%, the −a/aa
genotype about 30%, the −a/−a genotype about 5%, and
the genotype with five or morea-genes is <2% [8,13–
15]. Thus a-gene deletion appears to be protective
against CVA in children with SS. In addition, excess
a-genes may be a risk factor in the development of CVA
in SS.
The prevalence of CVA is higher in females than in
males in our patient population as shown in Table I.
About 700 children with SS are followed at Children’s
Hospital of Michigan. The 41 patients with CVA consti-
tute about 6% of the children with SS. The male/female
ratio in the 700 patients is about one. Thus the higher
prevalence of CVA in females (61%) may be due to the
fact that girls may not be more anemic than boys as is the
case in adults.
TABLE I. Alpha Genotype Distribution
2 a
3 a
n (%)
4 a
n (%)
5 a
n (%)
Total
n (%)
M 0 3 (7) 13 (32) 0 16 (39)
F 0 5 (12) 18 (44) 2 (5) 25 (61)
Total 0 8 (19) 31 (76) 2 (5) 41 (100)
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Determination of thebS-haplotypes in our patients
showed that CVA is most prevalent among patients with
the Ben/CAR haplotype followed by the Ben/Ben, Ben/
Sen, and CAR/CAR haplotypes, respectively (Table II).
The distribution ofbS-haplotypes among our patients
seems different from the reported haplotypes in patients
with SS at large as shown in Table III. Our study shows
that the prevalence of at least one chromosome with
atypical haplotype is higher in children with SS and
CVA. On the other hand, the prevalence of the Ben/Ben
haplotype is less in our patient population than that re-
ported in patients with SS at large. The apparent decrease
in this haplotype may be a reflection of the increased
prevalence in the other haplotypes mentioned above es-
pecially the atypical ones. Thus, if we delete the patients
with the atypical/X haplotype from Table III, the preva-
lence of the Ben/Ben haplotypes becomes 40%, the same
as in the other two previous reports.
Other subtle factors of the importance of thebS-
haplotypes in our patients include the fact that (i) the
three patients who were homozygous for the CAR hap-
lotype were all less than 10 years old, had foura-genes,
and were all males; (ii) the only patient who was homo-
zygous for the Sen haplotype was older than 10 years and
had four a-genes; (iii) both patients who had five
a-genes were females who were homozygous for atypi-
cal haplotypes; and (iv) three patients (7%) were hetero-
zygous for the Cameron haplotype. These findings,
though small in number, suggest that CAR and atypical
haplotypes may be more predictive of disease severity
than the other haplotypes.
Together the data suggest that female neonates with
four or morea-genes whosebS-haplotype is Ben/CAR or
atypical seem to be at a higher risk for CVA than other
patients. Moreover the CAR/CAR haplotype in associa-
tion with four a-genes in males also seems to pose a
higher risk for CVA than other combinations.
We emphasize that, because of the small patient popu-
lation we studied and the numerous variables in thea-ge-
notype andbS-haplotypes, formal statistical analysis was
not feasible. Despite the fact that these findings are pre-
liminary in nature due to the small sample size, they
nevertheless suggest that-globin genotype andbS-
haplotypes may have important implications in counsel-
ing and following children with SS, particularly when
discussing prenatal diagnosis and the merits of invasive
interventions such as bone marrow transplantation. A
progressive multi-institutional study on a larger group of
patients with or without CVA may clarify the signifi-
cance of our findings.
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